IOBT (IO Biotech, Inc.) יחס שווי שוק לשווי בספרים

IO Biotech, Inc. (IOBT) personalized tumor vaccine development is protected by T-cell stimulation patents, while stringent FDA requirements and R&D costs create a barrier to entry for competitors. The business relies on the treatment of severe melanoma, where costs are fully reimbursed by insurers, and the current metric stands at 5.09. This chart of share price action highlights the potential for a long-term monopoly driven by intellectual property protection.

This indicator compares the current market value of IO Biotech, Inc. (IOBT) with its net asset value, reflecting the gap between exchange quotes and the book value of capital. Analyzing the ratio of market value to balance sheet capital allows for an assessment of the business's degree of undervaluation, which is critical for a biotech firm with a diversified vaccine portfolio where market optimism often outpaces the actual value of assets.